Photos • Biography • Facebook • Twitter

From Wikipedia, the free encyclopedia

Thirumala-Devi Kanneganti
Born
Kothagudem, India
Alma mater
Known for
Awards
Scientific career
Fields Immunology
Institutions St. Jude Children's Research Hospital
Website https://www.stjude.org/kanneganti

Thirumala-Devi Kanneganti is an immunologist and is the Rose Marie Thomas Endowed Chair, Vice Chair of the Department of Immunology, and Member at St. Jude Children's Research Hospital. [1] She is also Director of the Center of Excellence in Innate Immunity and Inflammation at St. Jude Children's Research Hospital. Her research interests include investigating fundamental mechanisms of innate immunity, including inflammasomes and inflammatory cell death, PANoptosis, in infectious and inflammatory disease and cancer. [1]

Early life and education

Kanneganti is from Kothagudem, Telangana (United Andhra Pradesh), India. She received her undergraduate degree from Singareni Collieries Women's College, Kothagudem at Kakatiya University, where she majored in chemistry, zoology, and botany. [2] [3] She then received her M.Sc. and PhD from Osmania University in India. [3]

Career

Kanneganti began her career in research as a PhD student studying plant pathogens and fungal toxins. [4] She then went on to do postdoctoral fellowships at the University of Wisconsin and the Ohio State University studying fungal genetics and plant innate immunity. [2] [3] She transitioned to study mammalian innate immunity at the University of Michigan. [2] [3] She joined St. Jude Children's Research Hospital as an Assistant Member in the Immunology Department in 2007, where she has focused on studying inflammasomes and cell death. [1] [3] She was promoted to a full Member in 2013. She became Vice Chair of the Immunology Department in 2016 and was endowed with the Rose Marie Thomas Endowed Chair in 2017. [5] In 2022, she also became the Director of the Center of Excellence in Innate Immunity and Inflammation at St. Jude. [5] Kanneganti is among the most "Highly Cited Researchers" in the world due to the noteworthy impact of her findings in the fields of innate immunity, inflammation, and cell death. [1] [6] [7] [8] [9] [10]

Awards and honors

  • American Association of Immunology-BD Biosciences Investigator Award (2015) [11]
  • Vince Kidd Memorial Mentor of the Year Award (2015) [1]
  • Society for Leukocyte Biology Outstanding macrophage researcher Dolph O. Adams Award (2017) [12] [13]
  • American Society for Microbiology Eli Lilly and Company-Elanco Research Award (2017) [13]
  • Interferon and Cytokine Research Seymour & Vivian Milstein Award for Excellence (2018) [1] [4]
  • Clarivate/Web of Science list of Highly Cited Researchers (2017, 2018, 2019, 2020, 2021, 2022, 2023) [1] [6] [7] [8] [9] [10]
  • NIH R35 Outstanding Investigator Award (2020) [14] [15]
  • Fellow in the American Academy of Microbiology, American Society for Microbiology (2021) [16]
  • Outstanding Scientist Award, AAIS in Cancer Research (2022) [17]
  • Rosalind Franklin Society Special Award in Science (2023) [18]
  • Fellow in the American Association for the Advancement of Science (AAAS) (2023) [19]
  • American Association of Immunology-Thermo Fisher Meritorious Career Award (2024) [20]

Major contributions

Discovery of NLRP3 inflammasome, ZBP1-, RIPK1-, AIM2-, and NLRP12-PANoptosomes, and PANoptosis as therapeutic targets for infectious and inflammatory diseases and cancer

Kanneganti is well known for her breakthrough discoveries elucidating the functions of innate immune receptors, inflammasomes, and inflammatory cell death and for making fundamental contributions to inflammasome biology and the cell death field. [21] [22] [23] [24] [25] Her studies, along with those from other groups published in 2006, provided the first genetic evidence for the role of NLRP3 in the formation of the inflammasome, caspase-1 activation, and IL-1β/IL-18 maturation. [26] [27] These initial studies showed that microbial components, [21] [28] [29] ATP, [30] [31] and MSU crystals [32] activate the NLRP3 inflammasome.

Kanneganti discovered that Influenza A virus, Candida, and Aspergillus specifically activate the NLRP3 inflammasome and elucidated the physiological role of the NLRP3 inflammasome in host defense. [21] [33] [34] [35] [36] [37] Beyond infectious diseases, her lab also established the importance of the NLRP3 inflammasome in autoinflammatory diseases, [38] intestinal inflammation, [39] neuroinflammation, [40] cancer, [14] and metabolic diseases. [41]

Kanneganti's lab has also worked on the upstream regulatory mechanisms of NLRP3 and inflammasome-induced inflammatory cell death, pyroptosis. Her lab identified caspase-8 and FADD as expression and activation regulators of both the canonical and non-canonical NLRP3 inflammasome/pyroptosis. [42] Her group also characterized redundancies between caspase-1 and caspase-8 and between NLRP3 and caspase-8 in autoinflammatory disease and linked diet and the microbiome to these processes. [38] [43] [44] These studies demonstrated that the NLRP3 inflammasome/pyroptotic pathway is closely connected to the caspase-8–mediated programmed cell death pathway. [38] [42] [43] [44] This finding went against the dogma that existed at that time that caspase-8 and FADD were involved only in apoptosis. [42]

Following up on her original discovery that NLRP3 senses viral RNAs, [28] her lab discovered Z-DNA binding protein 1 ( ZBP1)/DAI as an innate immune sensor of influenza virus upstream of the NLRP3 inflammasome and cell death; however, this cell death was not consistent with any of the cell death pathways characterized at that time. [22] [45] This led Kanneganti to characterize ZBP1 as a regulator of PANoptosis, a unique innate immune inflammatory cell death pathway driven by caspases and RIPKs that is regulated by multiprotein PANoptosome complexes. [46] The multifaceted PANoptosome complexes have been visualized in single cells to integrate several molecular components, including ASC, caspase-8, and RIPK3. [47] [48] [49] [50] [51] [52] [53]

She then went on to establish that multiple PANoptosomes can contain different sensors and respond to different triggers:

  • The ZBP1-PANoptosome responds to influenza virus infection [22] [49] [54]
  • The RIPK1-PANoptosome responds to Yersinia infection and the inhibition of transforming growth factor beta-activated kinase 1 (TAK1), a molecule Kanneganti identified as a master regulator that maintains cellular homeostasis by negatively regulating the NLRP3 inflammasome and inflammatory cell death [47]
  • The AIM2-PANoptosome responds to Francisella and herpes simplex virus 1 infections [55] [51]
  • The NLRP12-PANoptosome responds to the combination of heme and PAMPs or TNF [56] [57]

Collectively, these studies identified ZBP1, AIM2, RIPK1, NLRP12, TAK1, and caspase-8 as master molecular switches of inflammasome activation and PANoptosis. Additionally, her group discovered that i nterferon regulatory factor 1 (IRF1), a critical regulator of inflammation and cell death, [58] regulates the activation of PANoptosis. [59]

PANoptosis is implicated in driving innate immune responses and inflammation. Kanneganti's research group has also further elucidated the molecular mechanisms of PANoptosis and showed that the enigmatic caspase-6 is critical for ZBP1-mediated NLRP3 inflammasome activation, PANoptosis, innate immune responses, and host defense against influenza virus. [49] Her lab also showed that coronavirus activates PANoptosis and that inhibiting the NLRP3 inflammasome or gasdermin D during coronavirus infection increases cell death and cytokine secretion rather than decreasing them. [60] Her research group also recently discovered the role of NINJ1, a key executioner of inflammatory cell death, in mediating PANoptosis following heat stress and infection, thereby identifying NINJ1 and PANoptosis effectors as potential therapeutic targets. [61]

Her group has also discovered the role of PANoptosis in cytokine storm, identifying TNF and IFN-γ as key cytokines that cause this inflammatory cell death pathway and lead to lung damage, organ failure, and lethality. Kanneganti's research group also showed that inhibiting TNF and IFN-γ could prevent lethality in SARS-CoV-2 infection, septic shock, hemophagocytic lymphohistiocytosis, and cytokine shock in mice. [62] This led her to advocate for the evaluation of a strategy to repurpose approved drugs that inhibit TNF-α or IFN-γ, as well as those that target other molecules in the PANoptosis pathway (e.g., JAK), to prevent the cytokine storm and pathogenesis. [62] [63] Additional work in Kanneganti's lab focusing on beta-coronaviruses showed that IFN induces ZBP1-mediated PANoptosis, which causes morbidity and mortality. These findings led her team to suggest that inhibiting ZBP1 may improve the efficacy of IFN therapy for COVID-19 and impact other infectious and inflammatory diseases where IFNs cause pathology. [64] [46]Beyond infectious disease and inflammatory syndromes, Kanneganti's group has also found that activating PANoptosis could be beneficial to eliminating cancer cells. Treatment of cancer cells with PANoptosis-inducing agents TNF and IFN-γ can reduce tumor size in preclinical models. [62] [65] [66] Her group also discovered a regulatory relationship between ADAR1 and ZBP1 that can be targeted with the combination of nuclear export inhibitors, such as selinexor, and IFN to drive ZBP1-mediated PANoptosis and regress tumors in preclinical models. [48] [67]

Overall, work from Kanneganti's lab has implicated PANoptosis in infectious, metabolic, hemolytic, neurologic, and autoinflammatory diseases and cancer. [22] [38] [47] [48] [49] [62] [46] [56]

Cytokine signaling and disease

Kanneganti's lab showed compensatory roles for NLRP3/caspase-1 and caspase-8 in the regulation of IL-1β production in osteomyelitis. [43] [44] Additionally, discoveries from her research group suggest that IL-1α and IL-1β can have distinct roles in driving inflammatory disease. [68] She identified the role of the IL-1α and RIPK1/TAK1/SYK signaling pathways in skin inflammation. [68] Furthermore, her studies also showed the role of another IL-1 family member, IL-33, in regulating immune responses and microbiota in the gut. [69] Overall, Kanneganti's lab discovered distinct and previously unrecognized functions of the cytokines IL-1α, IL-1β, and IL-33 and their signaling pathways in inflammatory diseases and cancer. [70] [43] [68] [69] [71]

Beyond her studies on IL-1 family members, her recent work on cytokine storm established TNF and IFN-γ as the key upstream cytokines that cause inflammatory cell death (PANoptosis), tissue and organ damage, and mortality, and she has suggested that strategies to target these cytokines or other molecules in their signaling pathway should be evaluated as therapeutic strategies in COVID-19, sepsis, and other diseases associated with cytokine storm. [62]

References

  1. ^ a b c d e f g "Thirumala-Devi Kanneganti, PhD". www.stjude.org. Retrieved 17 November 2019.
  2. ^ a b c Olsen, Patricia R. (27 October 2017). "After Witnessing Illness in India, She Seeks Ways to Fight It". The New York Times. ISSN  0362-4331. Retrieved 17 November 2019.
  3. ^ a b c d e "Thirumala-Devi Kanneganti: Immersed in Immunology". The Scientist Magazine. Retrieved 17 November 2019.
  4. ^ a b "Thirumala-Devi Kanneganti". The Milstein Awards. 29 June 2018. Archived from the original on 26 May 2022. Retrieved 17 November 2019.
  5. ^ a b "Thirumala-Devi Kanneganti, PhD". www.stjude.org. Retrieved 12 March 2024.
  6. ^ a b "Highly Cited Researchers".
  7. ^ a b "St. Jude researchers among the most highly cited in 2019". www.stjude.org. Retrieved 11 September 2020.
  8. ^ a b "St. Jude researchers are among the most highly cited scientists in the last decade". www.stjude.org. Retrieved 18 November 2020.
  9. ^ a b Kumar, Ruma. "St. Jude scientists make prestigious list of Highly Cited Researchers". www.stjude.org. Retrieved 19 November 2021.
  10. ^ a b "'Highly cited' St. Jude scientists named to annual list". www.stjude.org. Retrieved 12 March 2024.
  11. ^ "AAI-BD Biosciences Investigator Award". The American Association of Immunologists. Retrieved 23 April 2020.
  12. ^ "Dolph O. Adams Award". Society for Leukocyte Biology. Retrieved 23 April 2020.
  13. ^ a b Geiger, Terrence (19 October 2017). "Thirumala-Devi Kanneganti, PhD, honored for discoveries in immunology". St. Jude Progress. Retrieved 23 April 2020.
  14. ^ a b "St. Jude immunologist Thirumala-Devi Kanneganti, Ph.D., receives NCI Outstanding Investigator Award". www.stjude.org. Retrieved 3 October 2020.
  15. ^ "NCI Outstanding Investigator Award Recipients - National Cancer Institute". www.cancer.gov. 14 October 2015. Retrieved 2 November 2020.
  16. ^ "65 Fellows Elected into the American Academy of Microbiology". ASM.org. Retrieved 17 February 2021.
  17. ^ "Welcome to AAISCR". www.aaiscr.org. Retrieved 12 March 2024.
  18. ^ Kanneganti, Thirumala-Devi (August 2023). "Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Viral Immunology". Viral Immunology. 36 (6): 367. doi: 10.1089/vim.2023.29061.rfs2022. ISSN  0882-8245. S2CID  260840370.
  19. ^ "Thirumala-Devi Kanneganti, Ph.D. named 2022 AAAS Fellow". 31 January 2023. Retrieved 16 May 2023.
  20. ^ "AAI-Thermo Fisher Meritorious Career Award".
  21. ^ a b c Kanneganti, Thirumala-Devi; Ozören, Nesrin; Body-Malapel, Mathilde; Amer, Amal; Park, Jong-Hwan; Franchi, Luigi; Whitfield, Joel; Barchet, Winfried; Colonna, Marco; Vandenabeele, Peter; Bertin, John (9 March 2006). "Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3". Nature. 440 (7081): 233–236. Bibcode: 2006Natur.440..233K. doi: 10.1038/nature04517. hdl: 2027.42/62569. ISSN  1476-4687. PMID  16407888.
  22. ^ a b c d Kuriakose, Teneema; Man, Si Ming; Malireddi, R.K. Subbarao; Karki, Rajendra; Kesavardhana, Sannula; Place, David E.; Neale, Geoffrey; Vogel, Peter; Kanneganti, Thirumala-Devi (5 August 2016). "ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways". Science Immunology. 1 (2): aag2045. doi: 10.1126/sciimmunol.aag2045. ISSN  2470-9468. PMC  5131924. PMID  27917412.
  23. ^ Samir, Parimal; Kesavardhana, Sannula; Patmore, Deanna M.; Gingras, Sebastien; Malireddi, R. K. Subbarao; Karki, Rajendra; Guy, Clifford S.; Briard, Benoit; Place, David E.; Bhattacharya, Anannya; Sharma, Bhesh Raj (September 2019). "DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome". Nature. 573 (7775): 590–594. Bibcode: 2019Natur.573..590S. doi: 10.1038/s41586-019-1551-2. ISSN  1476-4687. PMC  6980284. PMID  31511697.
  24. ^ Karki, Rajendra; Lee, Ein; Place, David; Samir, Parimal; Mavuluri, Jayadev; Sharma, Bhesh Raj; Balakrishnan, Arjun; Malireddi, R. K. Subbarao; Geiger, Rechel; Zhu, Qifan; Neale, Geoffrey (3 May 2018). "IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation". Cell. 173 (4): 920–933.e13. doi: 10.1016/j.cell.2018.02.055. ISSN  1097-4172. PMC  5935577. PMID  29576451.
  25. ^ Man, Si Ming; Karki, Rajendra; Sasai, Miwa; Place, David E.; Kesavardhana, Sannula; Temirov, Jamshid; Frase, Sharon; Zhu, Qifan; Malireddi, R. K. Subbarao; Kuriakose, Teneema; Peters, Jennifer L. (6 October 2016). "IRGB10 Liberates Bacterial Ligands for Sensing by the AIM2 and Caspase-11-NLRP3 Inflammasomes". Cell. 167 (2): 382–396.e17. doi: 10.1016/j.cell.2016.09.012. ISSN  1097-4172. PMC  5074697. PMID  27693356.
  26. ^ Pobojewski, Sally. "Infection-fighting protein could be key to autoimmune disease". The University Record Online. University of Michigan. Retrieved 6 March 2020.
  27. ^ The Regents of the University of Michigan. "Methods and compositions for mediation of immune responses and adjuvant activity". Justia Patents. Retrieved 6 March 2020.
  28. ^ a b Kanneganti, Thirumala-Devi; Body-Malapel, Mathilde; Amer, Amal; Park, Jong-Hwan; Whitfield, Joel; Franchi, Luigi; Taraporewala, Zenobia F.; Miller, David; Patton, John T.; Inohara, Naohiro; Núñez, Gabriel (1 December 2006). "Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA". The Journal of Biological Chemistry. 281 (48): 36560–36568. doi: 10.1074/jbc.M607594200. ISSN  0021-9258. PMID  17008311.
  29. ^ Franchi, Luigi; Amer, Amal; Body-Malapel, Mathilde; Kanneganti, Thirumala-Devi; Ozören, Nesrin; Jagirdar, Rajesh; Inohara, Naohiro; Vandenabeele, Peter; Bertin, John; Coyle, Anthony; Grant, Ethan P. (June 2006). "Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages". Nature Immunology. 7 (6): 576–582. doi: 10.1038/ni1346. ISSN  1529-2908. PMID  16648852. S2CID  5846222.
  30. ^ Mariathasan, Sanjeev; Weiss, David S.; Newton, Kim; McBride, Jacqueline; O'Rourke, Karen; Roose-Girma, Meron; Lee, Wyne P.; Weinrauch, Yvette; Monack, Denise M.; Dixit, Vishva M. (9 March 2006). "Cryopyrin activates the inflammasome in response to toxins and ATP". Nature. 440 (7081): 228–232. Bibcode: 2006Natur.440..228M. doi: 10.1038/nature04515. ISSN  1476-4687. PMID  16407890.
  31. ^ Sutterwala, Fayyaz S.; Ogura, Yasunori; Szczepanik, Marian; Lara-Tejero, Maria; Lichtenberger, G. Scott; Grant, Ethan P.; Bertin, John; Coyle, Anthony J.; Galán, Jorge E.; Askenase, Philip W.; Flavell, Richard A. (March 2006). "Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1". Immunity. 24 (3): 317–327. doi: 10.1016/j.immuni.2006.02.004. ISSN  1074-7613. PMID  16546100.
  32. ^ Martinon, Fabio; Pétrilli, Virginie; Mayor, Annick; Tardivel, Aubry; Tschopp, Jürg (9 March 2006). "Gout-associated uric acid crystals activate the NALP3 inflammasome". Nature. 440 (7081): 237–241. Bibcode: 2006Natur.440..237M. doi: 10.1038/nature04516. ISSN  1476-4687. PMID  16407889.
  33. ^ Thomas, Paul G.; Dash, Pradyot; Aldridge, Jerry R.; Ellebedy, Ali H.; Reynolds, Cory; Funk, Amy J.; Martin, William J.; Lamkanfi, Mohamed; Webby, Richard J.; Boyd, Kelli L.; Doherty, Peter C. (17 April 2009). "The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1". Immunity. 30 (4): 566–575. doi: 10.1016/j.immuni.2009.02.006. ISSN  1097-4180. PMC  2765464. PMID  19362023.
  34. ^ Karki, Rajendra; Man, Si Ming; Malireddi, R. K. Subbarao; Gurung, Prajwal; Vogel, Peter; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi (11 March 2015). "Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection". Cell Host & Microbe. 17 (3): 357–368. doi: 10.1016/j.chom.2015.01.006. ISSN  1934-6069. PMC  4359672. PMID  25704009.
  35. ^ Lamkanfi, Mohamed; Malireddi, R. K. Subbarao; Kanneganti, Thirumala-Devi (31 July 2009). "Fungal zymosan and mannan activate the cryopyrin inflammasome". The Journal of Biological Chemistry. 284 (31): 20574–20581. doi: 10.1074/jbc.M109.023689. ISSN  1083-351X. PMC  2742822. PMID  19509280.
  36. ^ Briard, Benoit; Fontaine, Thierry; Samir, Parimal; Place, David E.; Muszkieta, Laetitia; Malireddi, R. K. Subbarao; Karki, Rajendra; Christgen, Shelbi; Bomme, Perrine; Vogel, Peter; Beau, Rémi (December 2020). "Galactosaminogalactan activates the inflammasome to provide host protection". Nature. 588 (7839): 688–692. Bibcode: 2020Natur.588..688B. doi: 10.1038/s41586-020-2996-z. ISSN  1476-4687. PMC  8086055. PMID  33268895.
  37. ^ "Research reveals how a fungal infection activates inflammation". www.stjude.org. Retrieved 19 November 2021.
  38. ^ a b c d "Diet affects mix of intestinal bacteria and the risk of inflammatory bone disease". www.stjude.org. Retrieved 11 September 2020.
  39. ^ Zaki, Md Hasan; Boyd, Kelli L.; Vogel, Peter; Kastan, Michael B.; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi (26 March 2010). "The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis". Immunity. 32 (3): 379–391. doi: 10.1016/j.immuni.2010.03.003. ISSN  1097-4180. PMC  2982187. PMID  20303296.
  40. ^ Shaw, Patrick J.; Barr, Maggie J.; Lukens, John R.; McGargill, Maureen A.; Chi, Hongbo; Mak, Tak W.; Kanneganti, Thirumala-Devi (28 January 2011). "Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity". Immunity. 34 (1): 75–84. doi: 10.1016/j.immuni.2010.12.015. ISSN  1097-4180. PMC  3057380. PMID  21236705.
  41. ^ Stienstra, Rinke; van Diepen, Janna A.; Tack, Cees J.; Zaki, Md Hasan; van de Veerdonk, Frank L.; Perera, Deshani; Neale, Geoffrey A.; Hooiveld, Guido J.; Hijmans, Anneke; Vroegrijk, Irene; van den Berg, Sjoerd (13 September 2011). "Inflammasome is a central player in the induction of obesity and insulin resistance". Proceedings of the National Academy of Sciences of the United States of America. 108 (37): 15324–15329. Bibcode: 2011PNAS..10815324S. doi: 10.1073/pnas.1100255108. ISSN  1091-6490. PMC  3174591. PMID  21876127.
  42. ^ a b c Gurung, Prajwal; Anand, Paras K.; Malireddi, R. K. Subbarao; Vande Walle, Lieselotte; Van Opdenbosch, Nina; Dillon, Christopher P.; Weinlich, Ricardo; Green, Douglas R.; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi (15 February 2014). "FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes". Journal of Immunology. 192 (4): 1835–1846. doi: 10.4049/jimmunol.1302839. ISSN  1550-6606. PMC  3933570. PMID  24453255.
  43. ^ a b c d Lukens, John R.; Gross, Jordan M.; Calabrese, Christopher; Iwakura, Yoichiro; Lamkanfi, Mohamed; Vogel, Peter; Kanneganti, Thirumala-Devi (21 January 2014). "Critical role for inflammasome-independent IL-1β production in osteomyelitis". Proceedings of the National Academy of Sciences of the United States of America. 111 (3): 1066–1071. Bibcode: 2014PNAS..111.1066L. doi: 10.1073/pnas.1318688111. ISSN  1091-6490. PMC  3903206. PMID  24395792.
  44. ^ a b c Lukens, John R.; Gurung, Prajwal; Vogel, Peter; Johnson, Gordon R.; Carter, Robert A.; McGoldrick, Daniel J.; Bandi, Srinivasa Rao; Calabrese, Christopher R.; Vande Walle, Lieselotte; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi (11 December 2014). "Dietary modulation of the microbiome affects autoinflammatory disease". Nature. 516 (7530): 246–249. Bibcode: 2014Natur.516..246L. doi: 10.1038/nature13788. ISSN  1476-4687. PMC  4268032. PMID  25274309.
  45. ^ Kesavardhana, Sannula; Kuriakose, Teneema; Guy, Clifford S.; Samir, Parimal; Malireddi, R. K. Subbarao; Mishra, Ashutosh; Kanneganti, Thirumala-Devi (7 August 2017). "ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death". The Journal of Experimental Medicine. 214 (8): 2217–2229. doi: 10.1084/jem.20170550. ISSN  1540-9538. PMC  5551577. PMID  28634194.
  46. ^ a b c "ZBP1 links interferon treatment and dangerous inflammatory cell death during COVID-19". www.stjude.org. Retrieved 2 June 2022.
  47. ^ a b c "Breaking the dogma: Key cell death regulator has more than one way to get the job done". St. Jude Children's Research Hospital press release. 23 December 2019. Retrieved 23 April 2020.
  48. ^ a b c "Promising preclinical cancer therapy harnesses a newly discovered cell death pathway". www.stjude.org. Retrieved 19 November 2021.
  49. ^ a b c d "Discovering the secrets of the enigmatic caspase-6". St. Jude Children's Research Hospital press release. 15 April 2020. Retrieved 23 April 2020.
  50. ^ Lee, SangJoon; Karki, Rajendra; Wang, Yaqiu; Nguyen, Lam Nhat; Kalathur, Ravi C.; Kanneganti, Thirumala-Devi (September 2021). "AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence". Nature. 597 (7876): 415–419. Bibcode: 2021Natur.597..415L. doi: 10.1038/s41586-021-03875-8. ISSN  1476-4687. PMC  8603942. PMID  34471287.
  51. ^ a b "The PANoptosome: a new frontier in innate immune responses". www.stjude.org. Retrieved 3 June 2022.
  52. ^ Malireddi, R. K. Subbarao; Kesavardhana, Sannula; Kanneganti, Thirumala-Devi (2019). "ZBP1 and TAK1: Master Regulators of NLRP3 Inflammasome/Pyroptosis, Apoptosis, and Necroptosis (PAN-optosis)". Frontiers in Cellular and Infection Microbiology. 9: 406. doi: 10.3389/fcimb.2019.00406. ISSN  2235-2988. PMC  6902032. PMID  31850239.
  53. ^ Wang, Yaqiu; Pandian, Nagakannan; Han, Joo-Hui; Sundaram, Balamurugan; Lee, SangJoon; Karki, Rajendra; Guy, Clifford S.; Kanneganti, Thirumala-Devi (28 September 2022). "Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method". Cellular and Molecular Life Sciences. 79 (10): 531. doi: 10.1007/s00018-022-04564-z. ISSN  1420-9071. PMC  9545391. PMID  36169732.
  54. ^ Zheng, Min; Karki, Rajendra; Vogel, Peter; Kanneganti, Thirumala-Devi (30 April 2020). "Caspase-6 Is a Key Regulator of Innate Immunity, Inflammasome Activation, and Host Defense". Cell. 181 (3): 674–687.e13. doi: 10.1016/j.cell.2020.03.040. ISSN  1097-4172. PMC  7425208. PMID  32298652.
  55. ^ Lee, SangJoon; Karki, Rajendra; Wang, Yaqiu; Nguyen, Lam Nhat; Kalathur, Ravi C.; Kanneganti, Thirumala-Devi (1 September 2021). "AIM2 forms a complex with Pyrin and ZBP1 to drive PANoptosis and host defense". Nature. 597 (7876): 415–419. Bibcode: 2021Natur.597..415L. doi: 10.1038/s41586-021-03875-8. ISSN  0028-0836. PMC  8603942. PMID  34471287.
  56. ^ a b "St. Jude finds NLRP12 as a new drug target for infection, inflammation and hemolytic diseases". www.stjude.org. Retrieved 1 September 2023.
  57. ^ Sundaram, Balamurugan; Pandian, Nagakannan; Mall, Raghvendra; Wang, Yaqiu; Sarkar, Roman; Kim, Hee Jin; Malireddi, R. K. Subbarao; Karki, Rajendra; Janke, Laura J.; Vogel, Peter; Kanneganti, Thirumala-Devi (22 June 2023). "NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs". Cell. 186 (13): 2783–2801.e20. doi: 10.1016/j.cell.2023.05.005. ISSN  1097-4172. PMC 10330523. PMID  37267949.
  58. ^ Fujita, T; Reis, L F; Watanabe, N; Kimura, Y; Taniguchi, T; Vilcek, J (December 1989). "Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways". Proceedings of the National Academy of Sciences. 86 (24): 9936–9940. Bibcode: 1989PNAS...86.9936F. doi: 10.1073/pnas.86.24.9936. ISSN  0027-8424. PMC  298617. PMID  2557635.
  59. ^ Sharma, Bhesh Raj; Karki, Rajendra; Rajesh, Yetirajam; Kanneganti, Thirumala-Devi (September 2023). "Immune regulator IRF1 contributes to ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome activation and inflammatory cell death (PANoptosis)". The Journal of Biological Chemistry. 299 (9): 105141. doi: 10.1016/j.jbc.2023.105141. ISSN  1083-351X. PMC  10494469. PMID  37557956.
  60. ^ Zheng, Min; Williams, Evan Peter; Malireddi, R. K. Subbarao; Karki, Rajendra; Banoth, Balaji; Burton, Amanda; Webby, Richard; Channappanavar, Rudragouda; Jonsson, Colleen Beth; Kanneganti, Thirumala-Devi (6 August 2020). "Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection". Journal of Biological Chemistry. 295 (41): 14040–14052. doi: 10.1074/jbc.ra120.015036. ISSN  0021-9258. PMC  7549031. PMID  32763970.
  61. ^ Han, Joo-Hui; Karki, Rajendra; Malireddi, R. K. Subbarao; Mall, Raghvendra; Sarkar, Roman; Sharma, Bhesh Raj; Klein, Jonathon; Berns, Harmut; Pisharath, Harshan; Pruett-Miller, Shondra M.; Bae, Sung-Jin; Kanneganti, Thirumala-Devi (26 February 2024). "NINJ1 mediates inflammatory cell death, PANoptosis, and lethality during infection conditions and heat stress". Nature Communications. 15 (1): 1739. Bibcode: 2024NatCo..15.1739H. doi: 10.1038/s41467-024-45466-x. ISSN  2041-1723. PMC  10897308. PMID  38409108.
  62. ^ a b c d e "In the lab, St. Jude scientists identify possible COVID-19 treatment". www.stjude.org. Retrieved 19 November 2020.
  63. ^ Karki, Rajendra; Kanneganti, Thirumala-Devi (August 2021). "The 'cytokine storm': molecular mechanisms and therapeutic prospects". Trends in Immunology. 42 (8): 681–705. doi: 10.1016/j.it.2021.06.001. ISSN  1471-4981. PMC  9310545. PMID  34217595. S2CID  235733135.
  64. ^ Karki, Rajendra; Lee, SangJoon; Mall, Raghvendra; Pandian, Nagakannan; Wang, Yaqiu; Sharma, Bhesh Raj; Malireddi, Rk Subbarao; Yang, Dong; Trifkovic, Sanja; Steele, Jacob A.; Connelly, Jon P. (19 May 2022). "ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection". Science Immunology. 7 (74): eabo6294. doi: 10.1126/sciimmunol.abo6294. ISSN  2470-9468. PMC  9161373. PMID  35587515.
  65. ^ Karki, Rajendra; Sharma, Bhesh Raj; Tuladhar, Shraddha; Williams, Evan Peter; Zalduondo, Lillian; Samir, Parimal; Zheng, Min; Sundaram, Balamurugan; Banoth, Balaji; Malireddi, R. K. Subbarao; Schreiner, Patrick (7 January 2021). "Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes". Cell. 184 (1): 149–168.e17. doi: 10.1016/j.cell.2020.11.025. ISSN  1097-4172. PMC  7674074. PMID  33278357.
  66. ^ Malireddi, R. K. Subbarao; Karki, Rajendra; Sundaram, Balamurugan; Kancharana, Balabhaskararao; Lee, SangJoon; Samir, Parimal; Kanneganti, Thirumala-Devi (21 July 2021). "Inflammatory Cell Death, PANoptosis, Mediated by Cytokines in Diverse Cancer Lineages Inhibits Tumor Growth". ImmunoHorizons. 5 (7): 568–580. doi: 10.4049/immunohorizons.2100059. ISSN  2573-7732. PMC  8522052. PMID  34290111.
  67. ^ Karki, Rajendra; Sundaram, Balamurugan; Sharma, Bhesh Raj; Lee, SangJoon; Malireddi, R. K. Subbarao; Nguyen, Lam Nhat; Christgen, Shelbi; Zheng, Min; Wang, Yaqiu; Samir, Parimal; Neale, Geoffrey (19 October 2021). "ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis". Cell Reports. 37 (3): 109858. doi: 10.1016/j.celrep.2021.109858. ISSN  2211-1247. PMC  8853634. PMID  34686350.
  68. ^ a b c Lukens, John R.; Vogel, Peter; Johnson, Gordon R.; Kelliher, Michelle A.; Iwakura, Yoichiro; Lamkanfi, Mohamed; Kanneganti, Thirumala-Devi (13 June 2013). "RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3". Nature. 498 (7453): 224–227. Bibcode: 2013Natur.498..224L. doi: 10.1038/nature12174. ISSN  1476-4687. PMC  3683390. PMID  23708968.
  69. ^ a b Malik, Ankit; Sharma, Deepika; Zhu, Qifan; Karki, Rajendra; Guy, Clifford S.; Vogel, Peter; Kanneganti, Thirumala-Devi (1 December 2016). "IL-33 regulates the IgA-microbiota axis to restrain IL-1α-dependent colitis and tumorigenesis". The Journal of Clinical Investigation. 126 (12): 4469–4481. doi: 10.1172/JCI88625. ISSN  1558-8238. PMC  5127671. PMID  27775548.
  70. ^ Lukens, John R.; Gross, Jordan M.; Kanneganti, Thirumala-Devi (2012). "IL-1 family cytokines trigger sterile inflammatory disease". Frontiers in Immunology. 3: 315. doi: 10.3389/fimmu.2012.00315. ISSN  1664-3224. PMC  3466588. PMID  23087690.
  71. ^ Gurung, Prajwal; Burton, Amanda; Kanneganti, Thirumala-Devi (19 April 2016). "NLRP3 inflammasome plays a redundant role with caspase 8 to promote IL-1β-mediated osteomyelitis". Proceedings of the National Academy of Sciences of the United States of America. 113 (16): 4452–4457. Bibcode: 2016PNAS..113.4452G. doi: 10.1073/pnas.1601636113. ISSN  1091-6490. PMC  4843439. PMID  27071119.
Retrieved from " https://en.wikipedia.org/?title=Thirumala-Devi_Kanneganti&oldid=1215827301"